Co-Diagnostics, Inc.
CODXCo-Diagnostics, Inc. is a molecular diagnostics company that develops, manufactures, and sells reagents and systems for the detection of infectious diseases and genetic traits.
Earnings
Next report
Nov 16, 2026 (in 3 months)Competitors
By market cap
By revenue growth
Profile
Co-Diagnostics, Inc. is a molecular diagnostics company that develops, manufactures, and sells reagents and systems for the detection of infectious diseases and genetic traits. The company utilizes its proprietary Co-Primers technology to provide high-specificity PCR testing with reduced false positives. Its value proposition centers on providing affordable, rapid, and reliable molecular testing for clinical laboratories and emerging point-of-care and at-home markets.
A low-cost provider of molecular diagnostics leveraging proprietary Co-Primers technology to avoid third-party royalties and improve multiplexing accuracy.
FAQ
- What is Co-Diagnostics, Inc.'s market cap?
- Co-Diagnostics, Inc. (CODX) has a market capitalization of $8.7M and trades on NASDAQ.
- Who are Co-Diagnostics, Inc.'s competitors?
- Co-Diagnostics, Inc.'s key competitors include Cepheid, Abbott Laboratories, Qiagen, and others. These companies compete in similar markets and product categories.
- Who does Co-Diagnostics, Inc. partner with?
- Co-Diagnostics, Inc.'s notable partners include Bill & Melinda Gates Foundation, National Institutes of Health, Arabian Eagle Manufacturing.
- What subsidiaries does Co-Diagnostics, Inc. have?
- Co-Diagnostics, Inc.'s subsidiaries include CoSara Diagnostics Pvt Ltd, CoMira Diagnostics.
- Where is Co-Diagnostics, Inc. headquartered?
- Co-Diagnostics, Inc. is headquartered in United States of America and employs approximately 155 people. It has been publicly traded since 2017.